Novo Nordisk (DE:NOVA)
NYSE:NOVA
NOVA Stock Chart & Stats
€34.30
€2.60(3.26%)
At close: 4:00 PM EST
€34.30
€2.60(3.26%)
Day’s Range― - ―
52-Week Range€30.45 - €71.80
Previous CloseN/A
Volume1.40K
Average Volume (3M)2.52K
Market Cap
€168.78B
Enterprise Value€1.43T
Total Cash (Recent Filing)€21.63B
Total Debt (Recent Filing)€146.38B
Price to Earnings (P/E)10.3
Beta0.78
Next Earnings
Aug 05, 2026EPS Estimate
0.71Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)27.45
Shares Outstanding3,390,128,000
10 Day Avg. Volume1,042
30 Day Avg. Volume2,519
Financial Highlights & Ratios
PEG Ratio8.17
Price to Book (P/B)7.42
Price to Sales (P/S)4.66
P/FCF Ratio49.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€38.97Price Target Upside13.60% Upside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)2.92
Revenue Forecast (FY)€39.48B
Bulls Say, Bears Say
Bulls Say
Obesity Franchise ExpansionRegulatory backing for a high‑dose single‑dose Wegovy pen materially strengthens product convenience and clinical differentiation. This durable improvement in dosing and planned EU launch should deepen patient uptake, extend market penetration, and entrench Novo Nordisk’s leadership in the fast‑growing obesity segment against new entrants.
Exceptional Profitability And MarginsConsistently very high gross and net margins reflect strong pricing power, manufacturing scale and differentiated biologic therapies. High margins support sustained R&D investment, dividends and buybacks, providing structural cash to fund pipeline and shareholder returns even if top‑line growth moderates.
Pipeline Diversification Into Rare DiseaseA successful Phase‑3 in sickle cell disease and planned regulatory filing broaden revenue sources beyond GLP‑1 and obesity. Orphan designations and meaningful clinical benefit create a durable specialty franchise with high pricing and payer interest, reducing single‑product concentration and supporting long‑term growth.
Bears Say
Rising LeverageMaterial rise in leverage reduces financial flexibility and raises interest‑rate sensitivity, limiting the firm's ability to absorb shocks or fund opportunistic M&A without higher funding costs. Higher debt increases risk to capital allocation priorities and could constrain investment or shareholder returns if macro or pricing pressures intensify.
Weakened Free Cash Flow ConversionLower and more volatile free cash flow versus prior years means less predictable internally generated cash for dividends, buybacks and reinvestment. Persistent weaker cash conversion suggests heavier reinvestment or working‑capital drag, increasing reliance on debt or capital markets and reducing margin for error in stressed scenarios.
Concentration Risk In GLP‑1 And U.S. ExposureHeavy dependence on GLP‑1/obesity products and large U.S. exposure concentrates commercial risk: payer actions, pricing pressures or competitor launches in core markets can disproportionately affect revenues. With growth moderating from the 2022–2024 surge, sustaining past expansion rates becomes harder and volatility may persist quarter to quarter.
Novo Nordisk News
NOVA FAQ
What was Novo Nordisk’s price range in the past 12 months?
Novo Nordisk lowest stock price was €30.45 and its highest was €71.80 in the past 12 months.
What is Novo Nordisk’s market cap?
Novo Nordisk’s market cap is €168.78B.
When is Novo Nordisk’s upcoming earnings report date?
Novo Nordisk’s upcoming earnings report date is Aug 05, 2026 which is in 58 days.
How were Novo Nordisk’s earnings last quarter?
Novo Nordisk released its earnings results on May 06, 2026. The company reported €0.905 earnings per share for the quarter, beating the consensus estimate of €0.767 by €0.138.
Is Novo Nordisk overvalued?
According to Wall Street analysts Novo Nordisk’s price is currently Undervalued.
Does Novo Nordisk pay dividends?
Novo Nordisk does not currently pay dividends.
What is Novo Nordisk’s EPS estimate?
Novo Nordisk’s EPS estimate is 0.71.
How many shares outstanding does Novo Nordisk have?
Novo Nordisk has 3,390,128,000 shares outstanding.
What happened to Novo Nordisk’s price movement after its last earnings report?
Novo Nordisk reported an EPS of €0.905 in its last earnings report, beating expectations of €0.767. Following the earnings report the stock price went up 2.556%.
Which hedge fund is a major shareholder of Novo Nordisk?
Currently, no hedge funds are holding shares in DE:NOVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Novo Nordisk Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€38.97 (13.60% Upside)
€38.97 (13.60% Upside)
Blogger Sentiment
Bullish
DE:NOVA Sentiment 70%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 92%
Bearish news 8%
Bearish news 8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-38.84%
12-Months-Change
Fundamentals
Return on Equity
66.36%
Trailing 12-Months
Asset Growth
21.75%
Trailing 12-Months
Company Description
Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
NOVA Company Deck
NOVA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mixed picture: strong commercial momentum in obesity and GLP-1 franchises (notably the successful Wegovy pill launch, robust GLP-1 volume share, and meaningful R&D readouts such as CagriSema and zenagamtide) alongside solid cash generation and shareholder returns. Offsetting these positives are substantial near-term headwinds driven by pricing pressure, policy impacts (MFN/MFP), loss of exclusivity risk, margin compression and a conservative 2026 outlook (adjusted sales and operating profit guidance of -5% to -13% CER). Management is bullish on long-term market expansion and pipeline potential but explicit near-term guidance and exceptional costs temper the tone. Overall, positives (product launches, R&D wins, market leadership and cash generation) are significant, but the company has signaled a pronounced near-term earnings challenge driven by pricing and policy — producing a balanced, watchful outlook.View all DE:NOVA earnings summariesNOVA Stock 12 Month Forecast
Average Price Target
€38.97
▲(13.60% Upside)
Technical Analysis
Options Prices
Currently, No data available
---